Sprunglinks

Home

You are here: Home

Do you know the targets of your ligand?

Pretest

Flow TriCEPS / TAMRA-TriCEPS / Services/Kit

Cell selection and optimization of binding conditions for target identification

More about

Target identification

LRC-TriCEPS / LRC-HATRIC Services

Identification of targets and off targets on the cell surface of living cells

More about

Confirmation

Flow TriCEPS combined with siRNA knock down

Knock down the identified targets and test if ligand binding is reduced

More about

How we support you

Dualsystems Biotech is a service provider for custom proteomics for industry and academia. We are a biotech company specialized in elucidating protein-protein interaction in living cells focusing at the cell membrane. We identify the targets of your extracellular ligands (small molecules, peptides, proteins, antibodies, ADC’s, Fc-fusion proteins, and viruses) using the ligand-receptor capture LRC-TriCEPS and the HATRIC-LRC platforms. During the interaction of your ligand of interest and its unknown targets and off-targets the cells are still alive and the unknown targets are in their natural microenvironment. There is no need to genetically modify the cells and any cell type (cell lines or primary cells) can be used.

We elucidate in a 3-step approach the mode of action of your ligand of interest.

With Flow-TriCEPS (Pretest) we developed a tool to visualize the binding of your ligand on cells using flow cytometry. Alternatively, with TAMRA-TriCEPS we can visualize the binding of TriCEPS coupled ligand to the cells also by confocal microscopy. During those pretests, we identify the best binding conditions (time, temperature, pH, co-factors, and cell activation) for your ligand of interest without the need of a detection antibody. Further, we provided Flow-TriCEPS as a kit so that you can test in your functional assays if your TriCEPS coupled ligand is still active. Flow-TriCEPS and TAMRA-TriCEPS couple the ligand by using primary amines (N-Term and Lysines) and since it contains a visualization function, binding can be detected by flow cytometry or confocal microscopy.

Once the optimal binding conditions are identified the next step can be initiated. In the identification studies, we use TriCEPS or HATRIC coupled ligand to treat the cells. The cells are mildly oxidized so that the second arm of TriCEPS / HATRIC binds with a covalent bond to the glycans of the targets/off-targets. The third arm of TriCEPS is used to enrich the surface proteins. Proteins are identified through bottom-up proteomics, relatively quantified and compared to one or several controls (we advise to use two controls). The most enriched proteins are the target candidates for the respective ligand. In general, we expect a low number of target candidates (less than 5).

In the third step, the identified target candidates can be downregulated using siRNA and if a reduced binding of the ligand of interest is observed with Flow-TriCEPS or TAMRA-TriCEPS compared to the wild type cells the identified candidates are confirmed.

News Dualsystems

News

Collaboration with aTyr Pharma Announces Research

Dualsystems Biotech is very excited to start a 3 year non-exclusive collaboration with aTyr Pharma to identify 10 novel therapeutic drug targets.
With our LRC-TriCEPS platform we can identify targets on living cells and have identified in the past many novel interactions.

Read more

Identify the mode of action using the TriCEPS platforms

Dualsystems-Biotech-Switzerland-Flow-TriCEPS-Pretest-Vizualization-function

Pretest

Flow TriCEPS / TAMRA-TriCEPS

  • Test the optimal binding conditions of your ligand to the unknown targets (time, temperature, pH) using flow cytometry or confocal microscopy
  • Find the best cell type for your identification experiment
  • Assess if co-factors are needed for your ligand to bind its targets
  • Use TriCEPS coupled ligand in your functional assay prior to the identification experiment
Dualsystems-Biotech-Switzerland-Target-identification-LRC-TriCEPS

Target identification

LRC-TriCEPS / LRC-HATRIC

  • Identification of the targets and off-targets of your ligand of interest on living cells using the LC-MS/MS based LRC-TriCEPS and LRC-HATRIC technology platforms
  • No genetic manipulation needed
  • Target proteins are in their natural microenvironment, the cell-membrane of living cells and therefore correctly modified and in the correct tertiary structure surrounded by their naturally occurring neighbouring proteins
Dualsystems-Biotech-Switzerland-Confirmation-of-targets-using-Flow-TriCEPS-2

Confirmation

Flow TriCEPS combined with siRNA knock down

  • Confirm the identified targets of your ligand by siRNA knock-down. Test by flow cytometry if the binding of your ligand is reduced when the identified target is knocked down
  • Can be performed for most targets unless they are relevant for cell survival
  • No antibodies against the targets needed

Elucidate the mode of action using the LRC-TriCEPS platforms

Download flyer

We identify targets / off-targets of your ligand

Interested?

Get in touch

Customers Testimonials – LRC-TriCEPS Service

Testimonials from our customers who have used the LRC-TriCEPS technology – in collaboration with Dualsystems Biotech AG.

Helmholtz Munich

We used the LRC-TriCEPS technology from Dualsystems to identify interacting proteins for a tumor-secreted factor on the surface of differentiated myotubes. The main interaction partner identified through the LRC-TriCEPS workflow could be confirmed using independent experimental methods. This discovery proved pivotal for elucidating the underlying mechanism of action responsible for the phenotypic effects we had observed and facilitated further development toward specific therapeutic targeting.

We highly appreciated the professional and dedicated support provided by the Dualsystems team throughout the project, which contributed to the smooth and successful execution of the study.

Dr. Mauricio Berriel Diaz
Deputy Director &
Head of Division Metabolism and Cancer
Institute for Diabetes and Cancer (IDC)



www.helmholtz-munich.de
2026-03-10T15:59:33+00:00
We used the LRC-TriCEPS technology from Dualsystems to identify interacting proteins for a tumor-secreted factor on the surface of differentiated myotubes. The main interaction partner identified through the LRC-TriCEPS workflow could be confirmed using independent experimental methods. This discovery proved pivotal for elucidating the underlying mechanism of action responsible for the phenotypic effects we had observed and facilitated further development toward specific therapeutic targeting. We highly appreciated the professional and dedicated support provided by the Dualsystems team throughout the project, which contributed to the smooth and successful execution of the study. Dr. Mauricio Berriel Diaz Deputy Director & Head of Division Metabolism and Cancer Institute for Diabetes and Cancer (IDC) www.helmholtz-munich.de

University Hospital of Lausanne (CHUV)

We collaborated with DualSystems Biotech AG to perform LRC-TriCEPS experiments aimed at identifying cellular factors involved in Zika virus infection. The entire process—from initial discussions through to data delivery—was carried out with exceptional professionalism and scientific rigor.

Thanks to their LRC-TriCEPS platform, we were able to identify a cellular factor playing a major role in Zika virus entry. This unique method was applied to living cells without the need for genetic modification. In our case, the method worked robustly across three different cell types. Notably, it enabled the identification of an unexpected target at the cell surface that would likely have been missed by standard screening approaches, as the protein lacks a classical membrane anchor. What impressed us most was that the implication of this target, discovered via their screening, was subsequently confirmed in our in vitro studies using different cellular models.

We greatly appreciated the collaboration with the DualSystems Biotech AG team. Their expertise, responsiveness, and willingness to support our project at every stage were key to its success. The data provided were of high quality and well presented, facilitating downstream interpretation and validation.

Milos Stojanov, PhD - Head of the Materno-fetal and Obstetrics Research Unit - University Hospital of Lausanne (CH)



 

Miloš Stojanov, PhD | Senior Lecturer (MER1)
Head of the Materno-fetal and Obstetrics Research Unit
Department Woman-mother-child (DFME)
1011 Lausanne
Tél: +41 21 314 05 17
2025-04-04T12:42:13+00:00
We collaborated with DualSystems Biotech AG to perform LRC-TriCEPS experiments aimed at identifying cellular factors involved in Zika virus infection. The entire process—from initial discussions through to data delivery—was carried out with exceptional professionalism and scientific rigor. Thanks to their LRC-TriCEPS platform, we were able to identify a cellular factor playing a major role in Zika virus entry. This unique method was applied to living cells without the need for genetic modification. In our case, the method worked robustly across three different cell types. Notably, it enabled the identification of an unexpected target at the cell surface that would likely have been missed by standard screening approaches, as the protein lacks a classical membrane anchor. What impressed us most was that the implication of this target, discovered via their screening, was subsequently confirmed in our in vitro studies using different cellular models. We greatly appreciated the collaboration with the DualSystems Biotech AG team. Their expertise, responsiveness, and willingness to support our project at every stage were key to its success. The data provided were of high quality and well presented, facilitating downstream interpretation and validation. Milos Stojanov, PhD - Head of the Materno-fetal and Obstetrics Research Unit - University Hospital of Lausanne (CH)   Miloš Stojanov, PhD | Senior Lecturer (MER1) Head of the Materno-fetal and Obstetrics Research Unit Department Woman-mother-child (DFME) 1011 Lausanne Tél: +41 21 314 05 17

OncoLille Cancer Institute

We aim to identify the ligand of a receptor, but due to the low affinity of the interaction other approaches that have been tried failed. Paul Helbling and the DualSystem team provided a great support and critical insights for performing the ligand identification using the LCR-TriCEPS technology. We found now a candidate ligand that we are currently validating with promising results. DualSystem team has been really professional and of great support in this process and we plan to work again with them in the future.



Best,

Silvia Gaggero, PhD
Mitra Lab, Inserm
OncoLille Cancer Institute
Lille, France


2024-06-06T12:25:14+00:00
We aim to identify the ligand of a receptor, but due to the low affinity of the interaction other approaches that have been tried failed. Paul Helbling and the DualSystem team provided a great support and critical insights for performing the ligand identification using the LCR-TriCEPS technology. We found now a candidate ligand that we are currently validating with promising results. DualSystem team has been really professional and of great support in this process and we plan to work again with them in the future. Best, Silvia Gaggero, PhD Mitra Lab, Inserm OncoLille Cancer Institute Lille, France

AstraZeneca

We needed to identify the target of an antibody from a phenotypic screening approach using a difficult iPSC-derived cell line and reached-out to DualSystems and their LRC-TriCEPS technology after an earlier attempt at target deconvolution using an array of membrane targets had failed.  The support I got from Paul Helbling and his team was great and as someone who was unfamiliar with the approach, I really appreciated the advice and guidance that I got. At the end of the process the top candidate from the analysis was confirmed as the target of the antibody – a brilliant result! Overall, a really positive experience and I would definitely recommend DualSystems.



James Dodgson
AstraZeneca
Cambridge, UK.
2023-05-24T20:08:08+00:00
We needed to identify the target of an antibody from a phenotypic screening approach using a difficult iPSC-derived cell line and reached-out to DualSystems and their LRC-TriCEPS technology after an earlier attempt at target deconvolution using an array of membrane targets had failed.  The support I got from Paul Helbling and his team was great and as someone who was unfamiliar with the approach, I really appreciated the advice and guidance that I got. At the end of the process the top candidate from the analysis was confirmed as the target of the antibody – a brilliant result! Overall, a really positive experience and I would definitely recommend DualSystems. James Dodgson AstraZeneca Cambridge, UK.

UCF College of Medicine

“DualSystems LRC-TriCEPS platform helped us in the identification of a novel allergen receptor. This finding was central to our recently published work and funded grant! DualSystems was very helpful during the entire process, if you are considering using this platform, do not hesitate. The process is straightforward and the support is excellent!”



Justine Tigno-Aranjuez, Ph.D.
Assistant Professor of Medicine
UCF College of Medicine
2023-03-16T06:40:12+00:00
“DualSystems LRC-TriCEPS platform helped us in the identification of a novel allergen receptor. This finding was central to our recently published work and funded grant! DualSystems was very helpful during the entire process, if you are considering using this platform, do not hesitate. The process is straightforward and the support is excellent!” Justine Tigno-Aranjuez, Ph.D. Assistant Professor of Medicine UCF College of Medicine

Cohbar

DualSystems' LRC-TriCEPS platform was exactly what we needed to identify potential targets and guide us in mechanism of action studies for our peptide program. They helped us every step of the way -- from understanding their capabilities, to guiding study design, and supporting sample preparation. The report they delivered exceeded our expectations and truly stands out from data reports we've received from other companies. They were readily available to answer questions and discuss concerns or outcomes. We are very encouraged by the results and are currently following up on the targets identified. We highly recommend working with DualSystems and incorporating the LRC-TriCEPS platform into your program. We look forward to working with the DualSystems team again in the future.



Dr. Lindsay Stark
Drug Discovery Scientist at CohBar
2023-01-18T08:14:48+00:00
DualSystems' LRC-TriCEPS platform was exactly what we needed to identify potential targets and guide us in mechanism of action studies for our peptide program. They helped us every step of the way -- from understanding their capabilities, to guiding study design, and supporting sample preparation. The report they delivered exceeded our expectations and truly stands out from data reports we've received from other companies. They were readily available to answer questions and discuss concerns or outcomes. We are very encouraged by the results and are currently following up on the targets identified. We highly recommend working with DualSystems and incorporating the LRC-TriCEPS platform into your program. We look forward to working with the DualSystems team again in the future. Dr. Lindsay Stark Drug Discovery Scientist at CohBar

Technical University of Munich

Technical University of Munich – Institute of Experimental Oncology and Therapy Research

Using LRC-TriCEPS, we aimed to identify novel direct cell surface receptors of our ligand of interest.
At any time, we experienced great support of Dualsystems Biotech. They kindly helped to find optimal conditions for our purposes and provided help with any kind of question before, during and after the experiment. LRC-TriCEPS allowed us to identify novel cell surface receptors of our ligand, which we could successfully validate in different cell types and with different biochemical assays. We can fully recommend Dualsystems Biotech and are looking forward to perform further analyses using LRC-TriCEPS.



Prof. Dr. rer. nat. Achim Krüger
Institute of Experimental Oncology and Therapy Research
Klinikum rechts der Isar, Technical University of Munich
2022-07-27T14:23:02+00:00
Technical University of Munich – Institute of Experimental Oncology and Therapy Research Using LRC-TriCEPS, we aimed to identify novel direct cell surface receptors of our ligand of interest. At any time, we experienced great support of Dualsystems Biotech. They kindly helped to find optimal conditions for our purposes and provided help with any kind of question before, during and after the experiment. LRC-TriCEPS allowed us to identify novel cell surface receptors of our ligand, which we could successfully validate in different cell types and with different biochemical assays. We can fully recommend Dualsystems Biotech and are looking forward to perform further analyses using LRC-TriCEPS. Prof. Dr. rer. nat. Achim Krüger Institute of Experimental Oncology and Therapy Research Klinikum rechts der Isar, Technical University of Munich

University of Miyazaki

We appreciate the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify a binding protein for our insulinotropic peptide



Hideyuki Sakoda, MD, PhD
Associate professor
Department of Biological Sciences, Faculty of Medicine, University of Miyazaki, Japan.
2022-04-19T11:45:22+00:00
We appreciate the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify a binding protein for our insulinotropic peptide Hideyuki Sakoda, MD, PhD Associate professor Department of Biological Sciences, Faculty of Medicine, University of Miyazaki, Japan.

Lund University Diabetes Centre

We wanted to use LRC-TriCEPS to characterise the mechanism of action of our ligand of interest. Not only were several candidate targets identified but we have successfully validated two of these receptors in insulin producing beta cells. DualSystems Biotech were very helpful and involved from study design, to experiments and reporting. Even after the initial report, DualSystems Biotech have answered follow up queries and provided assistance regarding publications. I highly recommend the LRC-TriCEPS technology and DualSystems Biotech and Paul Helbling and his team to work with.

 

Dualsystems-Testimonial-Lund-University

Dr. Claire L. Lyons,
Associate Researcher
Unit of Medical Protein Science
Lund University Diabetes Centre
Sweden
2021-10-25T05:58:59+00:00
We wanted to use LRC-TriCEPS to characterise the mechanism of action of our ligand of interest. Not only were several candidate targets identified but we have successfully validated two of these receptors in insulin producing beta cells. DualSystems Biotech were very helpful and involved from study design, to experiments and reporting. Even after the initial report, DualSystems Biotech have answered follow up queries and provided assistance regarding publications. I highly recommend the LRC-TriCEPS technology and DualSystems Biotech and Paul Helbling and his team to work with.   Dr. Claire L. Lyons, Associate Researcher Unit of Medical Protein Science Lund University Diabetes Centre Sweden

Australian National University

“We had a challenging project where we aimed to discover the receptor of our ligand of interest in primary human cells. Dualsystems Biotech took the challenge and provided outstanding support throughout the entire process, from the experimental design to data analysis. Using their LRC-TriCEPS technology, we could identify a candidate receptor and additional downstream interacting partners that we have now validated. We look forward to new collaborations and discoveries with Dr Paul Helbling and his team”. – Prof Carola Vinuesa, ANU



 

The Australian National University
Co-Director, Centre for Personalised Immunology, NHMRC Centre of Research Excellence
College of Health & Medicine
The Australian National University
2021-01-11T08:16:02+00:00
“We had a challenging project where we aimed to discover the receptor of our ligand of interest in primary human cells. Dualsystems Biotech took the challenge and provided outstanding support throughout the entire process, from the experimental design to data analysis. Using their LRC-TriCEPS technology, we could identify a candidate receptor and additional downstream interacting partners that we have now validated. We look forward to new collaborations and discoveries with Dr Paul Helbling and his team”. – Prof Carola Vinuesa, ANU   The Australian National University Co-Director, Centre for Personalised Immunology, NHMRC Centre of Research Excellence College of Health & Medicine The Australian National University

Harvard Medical School, Brigham and Women’s Hospital

We used DualSystems to help identify a potential novel receptor for a ligand that despite being studied for decades had unclear catabolism mechanisms involving its receptor mediated uptake. The DualSystems team will walk you through the process, including early validation of your ligand being used for this technology, data collection and analysis, and provide an easy to follow report on the findings. For anyone interested in receptor-ligand interactions, DualSystems and the TriCEPS approach is worth strongly considering involving in your research program, as it can quickly help identify receptors that would have been very difficult to do so without.

Maximillian Rogers, PhD
Research Scientist
Harvard Medical School, Brigham and Women's Hospital
Department of Medicine, Cardiovascular Division
Boston, MA
2020-11-09T13:27:52+00:00
We used DualSystems to help identify a potential novel receptor for a ligand that despite being studied for decades had unclear catabolism mechanisms involving its receptor mediated uptake. The DualSystems team will walk you through the process, including early validation of your ligand being used for this technology, data collection and analysis, and provide an easy to follow report on the findings. For anyone interested in receptor-ligand interactions, DualSystems and the TriCEPS approach is worth strongly considering involving in your research program, as it can quickly help identify receptors that would have been very difficult to do so without. Maximillian Rogers, PhD Research Scientist Harvard Medical School, Brigham and Women's Hospital Department of Medicine, Cardiovascular Division Boston, MA

Center for Biomolecular & Cellular Structure, Institute for Basic Science

“It was my great pleasure to collaborate with Dualsystems Biotech. We have been tested various proteomic analysis to identify the specific receptor for our secreted ligand. But, only LRC-TriCEPS experiment successfully gave us a right answer, because this receptor and ligand interactions were indeed relatively weaker than other general receptor and ligand interactions. The team very kindly consulted the whole experimental steps from the experimental design to the final data analysis. We are now going to use TriCEPS  again for several other secreted ligands with a great hope for discovery of new receptors. Best Regards, Ho Min Kim”



Associate Professor
Graduate School of Medical Science and Engineering, KAIST
Chief Investigator
Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS)
2020-08-12T13:02:47+00:00
“It was my great pleasure to collaborate with Dualsystems Biotech. We have been tested various proteomic analysis to identify the specific receptor for our secreted ligand. But, only LRC-TriCEPS experiment successfully gave us a right answer, because this receptor and ligand interactions were indeed relatively weaker than other general receptor and ligand interactions. The team very kindly consulted the whole experimental steps from the experimental design to the final data analysis. We are now going to use TriCEPS  again for several other secreted ligands with a great hope for discovery of new receptors. Best Regards, Ho Min Kim” Associate Professor Graduate School of Medical Science and Engineering, KAIST Chief Investigator Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS)

Department of Internal Medicine Erasmus MC

We were fortunate to partner with Dualsystems Biotech AG to discover cell-surface targets for the short-peptide ligand we had been working on for several years. We decided to try the LRC-TriCEPS approach to identify cell-surface binding partners for the ligand after several earlier aborted attempts using different techniques. Using LRC-TriCEPS we have identified targets that we have now been able to verify functionally and biochemically using other methods. It was a pleasure to work with Dr Paul Helbling and his team who were extremely helpful guiding us through the experimental process and assisting with analysis of the data. We were impressed by the quality of the data and the ease with which we were able to run the study.

Dualsystems_testimonial_erasmus_MCDr Patric Delhanty
Laboratory of Metabolism and Reproduction
Department of Internal Medicine
Erasmus MC
Rotterdam, The Netherlands
2020-04-28T11:54:52+00:00
We were fortunate to partner with Dualsystems Biotech AG to discover cell-surface targets for the short-peptide ligand we had been working on for several years. We decided to try the LRC-TriCEPS approach to identify cell-surface binding partners for the ligand after several earlier aborted attempts using different techniques. Using LRC-TriCEPS we have identified targets that we have now been able to verify functionally and biochemically using other methods. It was a pleasure to work with Dr Paul Helbling and his team who were extremely helpful guiding us through the experimental process and assisting with analysis of the data. We were impressed by the quality of the data and the ease with which we were able to run the study. Dr Patric Delhanty Laboratory of Metabolism and Reproduction Department of Internal Medicine Erasmus MC Rotterdam, The Netherlands

Seoul National University

"I have used many binding assays and was in the verge of giving up. Then I have contacted Dr. Paul Helbling and his group. The LRC-TriCEPS experiment was effective and let us go over the obstacle we had during the project. We look forward to using TriCEPS in the future".

Dualsystems_Biotech_Testimonials_Seoul_National_University

Chung Hwan Cho, Ph. D. candidate
Environmental Health Microbiology Laboratory
Department of Environmental Public Health
Seoul National University
2020-01-29T14:05:52+00:00
"I have used many binding assays and was in the verge of giving up. Then I have contacted Dr. Paul Helbling and his group. The LRC-TriCEPS experiment was effective and let us go over the obstacle we had during the project. We look forward to using TriCEPS in the future". Chung Hwan Cho, Ph. D. candidate Environmental Health Microbiology Laboratory Department of Environmental Public Health Seoul National University

Immuno-Oncology Discovery from Bristol-Myers Squibb published in Nature

„Vista is an acidic pH selective ligand for PSGL-1“

Identification of a new immune-oncology drug target using the LRC-TriCEPS platform on primary human T-cells.
2019-10-30T06:05:00+00:00
„Vista is an acidic pH selective ligand for PSGL-1“ Identification of a new immune-oncology drug target using the LRC-TriCEPS platform on primary human T-cells.

The University of Oklahoma – Health Sciences Center

I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped us develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed the interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.



Anne Kasus-Jacobi, PhD
Associate Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
2019-07-02T04:38:05+00:00
I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped us develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed the interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries. Anne Kasus-Jacobi, PhD Associate Professor of Research University of Oklahoma Health Sciences Center Department of Pharmaceutical Sciences Oklahoma City, Oklahoma, USA

CuroNZ Ltd

The team from DualSystems Biotech AG has been extremely helpful in delivering scientific advice for CuroNZ’s target identification journey. The quick turnaround time and the precision of NRP2945’s target identification in regard to the utilization of their TRICEPS technology impressed us very much. Meanwhile we could identify another NRP2945 receptor target that was identified by DualSystems as being recruited to the NRP2945-activated membrane receptor complex. An absolute pleasure to work with Paul Helbling’s team.

Dualsystems-Biotech-Testimonial-Curonz Logo

Frank Sieg, PhD
CSO
CuroNZ Ltd
Mangawhai in New Zealand
2019-02-20T12:18:04+00:00
The team from DualSystems Biotech AG has been extremely helpful in delivering scientific advice for CuroNZ’s target identification journey. The quick turnaround time and the precision of NRP2945’s target identification in regard to the utilization of their TRICEPS technology impressed us very much. Meanwhile we could identify another NRP2945 receptor target that was identified by DualSystems as being recruited to the NRP2945-activated membrane receptor complex. An absolute pleasure to work with Paul Helbling’s team. Frank Sieg, PhD CSO CuroNZ Ltd Mangawhai in New Zealand

University of Pittsburgh

It was a pleasure working with Paul Helbling and his team. I was impressed by their attention to detail, and optimization of all cell conditions to produce the most reliable possible results. They kept me informed at every stage of the process and shared data as soon as they were able to. Using their LRC-TriCEPS platform, we were able to follow leading candidates as binding partners for our cardiac targeting peptide and identified the most likely binding partner.

Dualsystems-Logo-University-of-Pittsburgh

Maliha Zahid, M.D., Ph.D.
Assistant Professor
Departement of Developmental Biology
University of Pittsburgh
2018-11-15T19:35:14+00:00
It was a pleasure working with Paul Helbling and his team. I was impressed by their attention to detail, and optimization of all cell conditions to produce the most reliable possible results. They kept me informed at every stage of the process and shared data as soon as they were able to. Using their LRC-TriCEPS platform, we were able to follow leading candidates as binding partners for our cardiac targeting peptide and identified the most likely binding partner. Maliha Zahid, M.D., Ph.D. Assistant Professor Departement of Developmental Biology University of Pittsburgh

University of Oklahoma Health Sciences Center

I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped our lab develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed this interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.University of Oklahoma Health Sciences Center-Logo

 

Anne Kasus-Jacobi, PhD
Assistant Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
2018-04-23T11:45:16+00:00
I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped our lab develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed this interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.   Anne Kasus-Jacobi, PhD Assistant Professor of Research University of Oklahoma Health Sciences Center Department of Pharmaceutical Sciences Oklahoma City, Oklahoma, USA

Biomedical Research Institute

PUBLICATION:  Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J.  Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479.

The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics.  However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays.   We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.LABioMed-Logo(Quim) Madrenas, MD, PhD, FCAHS
Chief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, USA
2018-04-19T11:18:18+00:00
PUBLICATION:  Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J.  Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479. The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics.  However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays.   We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.(Quim) Madrenas, MD, PhD, FCAHS Chief Scientific Officer Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Torrance, USA

QIMR Berghofer Medical Research Institute

“With the help of the team at Dualsystems we confirmed a potential receptor which has lead to a Nature paper submission and successful funding of a research grant. The LRC-TriCEPS experiment was straightforward and the process was cost effective. We look forward to using TriCEPS in the future.”QIMR Berghofer Medical Research Institute LogoAnita Burgess  |  PhD
Hepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia
2017-12-12T13:21:33+00:00
“With the help of the team at Dualsystems we confirmed a potential receptor which has lead to a Nature paper submission and successful funding of a research grant. The LRC-TriCEPS experiment was straightforward and the process was cost effective. We look forward to using TriCEPS in the future.”Anita Burgess  |  PhD Hepatic Fibrosis Group QIMR Berghofer Medical Research Institute, Australia

University of Miami, Miller School of Medicine

We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. Read more
I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.
Dualsystems-Logo-University of Miami, Miller School of MedicineDr Karina Galoian
Research associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA
2017-11-16T08:07:04+00:00
We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. Read more I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration. Dr Karina Galoian Research associate professor University of Miami, Miller School of Medicine Department of Orthopedic surgery Miami, Florida, USA

Münster University Hospital (UKM)

"Dualsystems Biotech’s approach to receptor identification with the TriCEPS reagent gave us a powerful platform with great support for a successful and fast data generation, when conventional approaches had previously failed."Münster University Hospital (UKM) Dr. rer. nat. Martin Herold
Working group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany
2017-08-24T14:48:20+00:00
"Dualsystems Biotech’s approach to receptor identification with the TriCEPS reagent gave us a powerful platform with great support for a successful and fast data generation, when conventional approaches had previously failed."Dr. rer. nat. Martin Herold Working group from Prof. Dr. med. Luisa Klotz Münster University Hospital (UKM), Germany

University of Manitoba

"Every aspect of our experience with Dualsystems Biotech was outstanding.  They provided excellent customer service and technical support throughout the entire process.  Their LRC-TriCEPS technology allowed us to identify several new candidate receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues for our research."

University of Manitba-logoSari S. Hannila, PhD
Associate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre
Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba
2017-06-12T10:05:43+00:00
"Every aspect of our experience with Dualsystems Biotech was outstanding.  They provided excellent customer service and technical support throughout the entire process.  Their LRC-TriCEPS technology allowed us to identify several new candidate receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues for our research." Sari S. Hannila, PhD Associate Professor, Department of Human Anatomy and Cell Science Associate Member, Spinal Cord Research Centre Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba

The Rockefeller University

"We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question."rockefeller-university-logoManish Ponda, M.D., M.S.
Assistant Professor of Clinical Investigation
The Rockefeller University
2016-10-10T14:21:51+00:00
"We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question."Manish Ponda, M.D., M.S. Assistant Professor of Clinical Investigation The Rockefeller University

Medizinische Hochschule Hannover

“With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.”

mh-hannover-logoDr. rer. nat. Inga Sörensen-Zender
Postdoc
Medizinische Hochschule Hannover

 
2016-09-26T10:26:51+00:00
“With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.” Dr. rer. nat. Inga Sörensen-Zender Postdoc Medizinische Hochschule Hannover  

East Tennessee State University

“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”Logo East Tennessee State UniversityJonathan M Peterson
Assistant Professor
East Tennessee State University
2016-05-30T15:20:03+00:00
“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”Jonathan M Peterson Assistant Professor East Tennessee State University

Igenica Biotherapeutics

«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»Igenica-Biotherapeutics-logoDr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics
2016-05-09T11:13:08+00:00
«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»Dr. Edward van der Horst, Senior Director, Preclinical Development Igenica Biotherapeutics

Centro de Estudos de Doenças Crónicas

New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »

Cedoc-logoAlisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas
2015-02-24T07:32:40+00:00
New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo « The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified » Alisson M. Gontijo, Principal Investigator at CEDOC Centro de Estudos de Doenças Crónicas

Washington University School of Medicine

"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems".Washington_University_in_StFumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine
2015-02-17T14:30:12+00:00
"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems".Fumihiko Urano, MD, PhD Samuel E. Schechter Professor of Medicine Washington University School of Medicine

University of California San Francisco

"We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor." indexDe'Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)
2015-02-17T14:27:53+00:00
"We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor." De'Broski R. Herbert Ph.D. Assistant Professor in Residence University of California San Francisco (UCSF)

LRC-TriCEPS customers worldwide

Over 200 satisfied customers from 28 countries.

Customers worldwide
10+

Years working with LRC-TriCEPS

200+

LRC-TriCEPS clients served

50+

Cell types used for LRC-TriCEPS

23+

Years of experience

Areas of expertise

Specialized in identifying targets and off targets on living cells to elucidate the mode of action.
Experts in proteomics, LC-MS/MS analyses, and cell biology.

Affinity & receptor expression

Using antibodies with different affinities against the same targets on cells expressing the targets on different levels.

More about

Example of LRC-TriCEPS

Example of the results of an LRC-TriCEPS experiment with the deliverables.

More about

LRC-TriCEPS on human primary T-cells

Primary T-cells are used for target identification and to elucidate cell-cell interactions.

More about

Company

Dualsystems Biotech is a provider of proteomics services for industry and academia.

More about

FAQs

Find answers to your questions or just give us a call.

More about

Publication

Find publications using LRC-TriCEPS or HATRIC-LRC platforms for target identification.

More about

LRC-TriCEPS publications

Publications

LRC-TriCEPS / HATRIC-LRC Publications

Concerning the LRC-TriCEPS or HATRIC-LRC platforms.

Presented at the annual meeting of the International Society for Extracellular Vesicles (ISEV) 2025 Annual Meeting in April

PDF for download

Apolipoprotein A-I priming via SR-BI and ABCA1 receptor binding upregulates mitochondrial metabolism to promote insulin secretion in INS-1E cells

Link PDF

Link to the News Release Details 

PDF

Identification of key extracellular binding proteins implicate role in inflammation and fibrosis for alanyl- and aspartyl-tRNA synthetases

Latrophilin-2 is a novel receptor of LRG1 that rescues vascular and neurological abnormalities and restores diabetic erectile function – Diabetes mellitus (DM) is a chronic metabolic disorder that involves endothelial dysfunction and neuropathy and can lead to multiple complications, including cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and retinopathy1. DM is also a major cause of erectile dysfunction (ED), which is a manifestation of microangiopathy and neuropathy1. Approximately 50–75% of male diabetic patients have ED2. Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used first-line treatment options for ED; however, these agents are ineffective in ~30% of patients and ultimately cannot rescue angiopathy and neuropathy in diabetic ED patients3. Tested alternative therapeutic options for ED include various angiogenic or neurotrophic factors, such as COMP-Ang1, vascular endothelial growth factor (VEGF), dickkopf2, neurotrophin-3 (NT3), and brain-derived neurotrophic factor (BDNF)4,5,6,7,8; however, these treatments have shown limited success in clinical trials.

Experimental & Molecular Medicine volume 54, pages626–638 (2022) Cite this article

PDF  and Link to the nature.com

Nature Microbiol (2021) https://doi.org/10.1038/s41564-021-00880-5

iScience  Volume 23, ISSUE 12, 101810, December 18, 2020, DOI:https://doi.org/10.1016/j.isci.2020.101810

International Journal of Molecular Sciences. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352787/  

METHODS. We used a TriCEPS-based, ligand-receptor glycocapture method to identify the
binding partners of CAP37 on live human corneal epithelial cells using the hTCEpi cell
line. We used an ELISA method to confirm binding with identified partners and test the
binding with CAP37-derived peptides. We used a reporter cell line to measure activation
of the identified membrane receptor by CAP37 and derived peptides.

Nature Immunology  volume 21, pages13–16 (2020)

https://doi.org/10.1016/j.trsl.2019.07.008, Translational Research Volume 213, Sörensen-Zender et al.

https://www.nature.com/articles/s41586-019-1674-5 Nature volume 574, pages565–570 (2019)  

https://www.nature.com/articles/s41598-020-71519-4 Mehta, N., Maddineni, S., Kelly, R.L. et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep 10, 15171 (2020). https://doi.org/10.1038/s41598-020-71519-4 PDF

Phage resistance at the cost of virulence: Listeria monocytogenes serovar 4b requires galactosylated teichoic acids for InlBmediated invasion
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008032 October 7, 2019
PDF

Nature Communications volume 10, Article number: 4408 (2019) https://doi.org/10.1038/s41467-019-12315-1

European Biopharmaceutical Review April 2019, pages 16-20 / Maria P. Pavlou and Paul Helbling / White -Paper PDF

BMC Research Notes 2018 11:863 https://doi.org/10.1186/s13104-018-3974-5 Laura A. Lopez‑Garcia, Levent Demiray, Sandra Ruch‑Marder, Ann‑Katrin Hopp, Michael O. Hottiger, Paul M. Helbling and Maria P. Pavlou Received: 28 October 2018 – Accepted: 30 November 2018- Published: 5 December 2018 PDF

Maliha Zahid, Kyle S. Feldman, Gabriel Garcia-Borrero, Timothy N. Feinstein, Nicholas Pogodzinski, Xinxiu Xu, Raymond Yurko, Michael Czachowski , Yijen L. Wu, Neale S. Mason and CeciliaW. Lo Biomolecules 2018, 8, 147; doi:10.3390/biom8040147 Received: 24 September 2018 / Accepted: 8 November 2018 / Published: 14 November 2018

Francis P Roche, Ilkka Pietilä, Hiroshi Kaito, Elisabet O Sjöström, Nadine Sobotzki, Oriol Noguer, Tor Persson Skare, Magnus Essand, Bernd Wollscheid, Michael Welsh and Lena Claesson-Welsh DOI: 10.1158/1535-7163.MCT-18-0097 Received January 27, 2018, Revision received April 21, 2018, Accepted June 19, 2018, Copyright ©2018, American Association for Cancer Research. PDF

Lisa Lasswitz, Naresh Chandra, Niklas Arnberg, Gisa Gerold jmb Journal of Molecular Biology, doi.org/10.1016/j.jmb.2018.04.039 Received 15 February 2018, Revised 24 April 2018, Accepted 30 April 2018, Available online 7 May 2018.

Contact

Please contact us for more information

Please contact us for more information

*Mandatory fields – please complete

Dualsystems Biotech AG

Dualsystems Biotech AG
Dr. Paul Helbling
Grabenstrasse 11a
8952 Schlieren
Switzerland

phone +41 44 738 50 00
fax +41 44 738 50 05

Contact Dr. Paul Helbling to discuss how we can support your projects.

info@dualsystems.com

Dualsystems Biotech is located in Schlieren (Zurich), close to the railway station.

Dualsystems-Biotech-AG-Grabenstrasse-11a-8952-Schlieren-Switzerland-Building-2
DO YOU WANT TO TEST IT NOW?
Transport not incl. Your Information will never be shared with any third party.
To get pretest TriCEPS Material please contact us!

Identify the targets of your ligand on the living cells. Prior to the main experiment get free TriCEPS Material to test the functionality of your TriCEPS coupled ligand.
  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses
DO YOU WANT TO TALK TO US?
Your information will never be shared with any third party.
LRC-TriCEPS to identify targets on the surface of living cells.

Please provide your email address and we will contact you to arrange a call.
  • Small molecules
  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses